FDA’s "Broken Bureaucracy" Makes Issa’s Hit List Of Reform Targets
This article was originally published in The Gray Sheet
Executive SummaryIncoming House Oversight and Government Reform Committee Chairman Darrell Issa, R-Calif., considers FDA a “broken bureaucracy” ripe for reform.
You may also be interested in...
Vertex is hoping for EU approval in Q4 of its cystic fibrosis triple combination therapy, Trikafta. It wants the same licence in the EU as it has in the US, where the product has already become a best seller for the company.
Sawai’s sales increased on the back of a good performance from recently-launched products in the first nine months of its financial year. However, given the competitive environment the Japanese company is continuing to stick to its full-year forecasts.